Your session is about to expire
← Back to Search
Pembrolizumab +/− Defactinib for Pancreatic Cancer
Study Summary
This trial will test a new combination of drugs to treat pancreatic cancer. The drugs will be given before and after surgery, and the trial will compare the effectiveness of the combination with and without a third drug.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My condition can be treated with surgery.I have pancreatic cancer.I have been treated with a FAK inhibitor before.I have an autoimmune disease treated within the last 2 years.I have another cancer that is getting worse or needed treatment in the last 2 years.I am fully active or can carry out light work.I have not had any drug treatments for pancreatic cancer.I have not received a live vaccine in the last 30 days.My cancer was stage IIb or lower when diagnosed.I haven't taken immunosuppressive drugs in the last 7 days.I am infected with HIV or hepatitis B or C.I do not have any severe illnesses that would stop me from following the study's requirements.I am currently being treated for an infection with medication.My organs are functioning well according to recent tests.I am not pregnant or breastfeeding.I haven't taken any growth factor medications in the last 14 days.I have had treatments like chemotherapy or radiotherapy for pancreatic cancer.I have previously been treated with specific immune therapies for cancer.I have had lung inflammation not caused by an infection.I have had an organ transplant.I am 18 years old or older.
- Group 1: Arm A - Pembrolizumab and Defactinib
- Group 2: Arm B - Pembrolizumab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What have been the observed risks associated with Pembrolizumab use?
"With prior safety data, Pembrolizumab was given a score of 2 since this is only Phase 2 trial. As such, there has yet to be evidence proving its efficacy."
In what ways has Pembrolizumab been used therapeutically?
"Medical experts often use Pembrolizumab to treat malignant neoplasms, as well as unresectable melanoma, cases of microsatellite instability high and disease progression after chemotherapy."
Could you provide an overview of all the trials that have featured Pembrolizumab?
"At the current moment, 969 clinical trials concerning Pembrolizumab are ongoing, with 122 in Phase 3. Whilst Houston Texas hosts a majority of these studies, 37286 other locations have been assigned to conduct research into this drug."
Does the trial extend to those who are more than three decades old?
"According to the requirements, those wishing to participate must be between 18 and 100. For minors there are 36 clinical trials available, while senior citizens may choose from a selection of 1763 studies."
Am I eligible to partake in this medical study?
"Those wishing to join this clinical trial must possess adenocarcinoma and be within the age range of 18-100. The recruitment process is targeting a total of 36 individuals."
What is the maximum number of participants being admitted to this clinical research?
"Affirmative. On clinicaltrials.gov, one can find that this trial commenced on June 4th 2019 and was recently updated on March 22nd 2022. The study requires 36 recruits to be gathered from two medical sites."
Is there still a possibility for individuals to become involved in this experiment?
"As indicated by the information hosted on clinicaltrials.gov, this investigation is presently seeking participants. It was first advertised in June 2019 and has been revised as recently as March 2022."
Share this study with friends
Copy Link
Messenger